FDA Committee votes against AstraZeneca anaemia treatment
16th Jul 2021 08:03
(Sharecast News) - AstraZeneca said on Friday that the US Food and Drug Administration has voted against the use of its roxadustat drug for the treatment of anaemia in chronic kidney disease in non-dialysis dependent (NDD) and dialysis-dependent (DD) adults.
Read moreCMA clears AstraZeneca's $39bn Alexion acquisition
14th Jul 2021 07:32
(Sharecast News) - AstraZeneca said on Wednesday that its proposed $39bn acquisition of US drug developer Alexion is expected to close on 21 July, after receiving clearance from the UK Competition and Markets Authority.
Read moreThursday broker round-up
8th Jul 2021 13:04
(Sharecast News) - Croda International: HSBC upgrades to buy with a target price of 8,600p.
Read moreAstraZeneca asthma drug gets priority FDA review
8th Jul 2021 07:39
(Sharecast News) - AstraZeneca on Thursday said its experimental drug tezepelumab had been given a priority review by the US Food and Drug Administration for potential approval as a treatment for asthma.
Read moreAstraZeneca's Alexion acquisition cleared by European Commission
6th Jul 2021 07:44
(Sharecast News) - AstraZeneca said on Tuesday that its $39bn proposed acquisition of US drug developer Alexion has been cleared by the European Commission.
Read moreGermany advised to combine AstraZeneca and mRNA vaccines to brake Delta variant
2nd Jul 2021 11:17
(Sharecast News) - Germany's government committee on vaccinations believes combining the Covid-19 vaccine made by AstraZeneca and mRNA ones such as Pfizer's is the best way to combat the so-called Delta variant.
Read moreJohnson and Johnson Covid-19 shot effective against Delta variant
2nd Jul 2021 08:04
(Sharecast News) - Johnson&Johnson's Covid-19 vaccine provides protections against all variants, including the increasingly predominant Delta variant.
Read moreMonday broker round-up
28th Jun 2021 13:28
(Sharecast News) - St James Place: HSBC downgrades to hold with a target price of 1,525p.
Read moreAstraZeneca's Forxiga recommended for EU approval
28th Jun 2021 07:47
(Sharecast News) - AstraZeneca said on Monday that 'Forxiga', or dapagliflozin, has been recommended for approval in the European Union for the treatment of chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D).
Read moreAstraZeneca, MSD prostate cancer drug gets China green light
24th Jun 2021 07:34
(Sharecast News) - AstraZeneca and MSD's Lynparza prostate cancer drug has been granted conditional approval in China after a successful phase three trial, the companies said on Thursday.
Read moreWednesday broker round-up
23rd Jun 2021 13:04
(Sharecast News) - Hunting: JP Morgan upgrades overweight with a target price of 290p.
Read moreDelta plus variant reclassified as 'variant of concern', experts sanguine for now
23rd Jun 2021 10:47
(Sharecast News) - India's Health Ministry has upgraded a new variant of Covid-19 dubbed Delta plus to a "variant of concern".
Read moreAstraZeneca's 'Orpathys' gets conditional approval in China
23rd Jun 2021 07:33
(Sharecast News) - AstraZeneca announced on Wednesday that 'Orpathys', or savolitinib, has been granted conditional approval in China to treat patients with non-small cell lung cancer (NSCLC), with MET exon 14 skipping alterations who have progressed following prior systemic therapy or were unable to receive chemotherapy.
Read moreAstraZeneca given EU approval for use of Koselugo in children
22nd Jun 2021 08:25
(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that its Koselugo drug had been approved for use in children with neurofibromatosis type 1 and plexiform neurofibromas across the European Union.
Read moreThursday broker round-up
17th Jun 2021 13:49
(Sharecast News) - Pets At Home: Liberum upgrades to buy with a target price of 510p.
Read more